for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Obalon Therapeutics Inc

OBLN.OQ

Latest Trade

2.16USD

Change

-0.08(-3.57%)

Volume

59,598

Today's Range

2.09

 - 

2.24

52 Week Range

1.66

 - 

34.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.24
Open
2.24
Volume
59,598
3M AVG Volume
11.16
Today's High
2.24
Today's Low
2.09
52 Week High
34.00
52 Week Low
1.66
Shares Out (MIL)
5.57
Market Cap (MIL)
12.48
Forward P/E
-0.24
Dividend (Yield %)
--

Latest Developments

More

Empery Asset Management Reports A 9.99% Passive Stake In Obalon Therapeutics As Of August 2

Obalon Reports Q2 2019 Results

Obalon Therapeutics Says Offered Voluntary Separation Packages To About 15 Employees

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Obalon Therapeutics Inc

Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Industry

Medical Equipment & Supplies

Contact Info

5421 Avenida Encinas Ste F

+1.858.4802400

http://www.obalon.com/

Executive Leadership

Andrew P. Rasdal

Chairman of the Board

William J. Plovanic

President, Chief Financial Officer

Nooshin Hussainy

Vice President - Finance

Steve Johnson

Vice President - Operations

Matthew Norwood

Vice President of Sales

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-48.500

2017

-20.800

2018

-19.600

2019(E)

-9.205
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.74
Price To Book (MRQ)
0.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
59.62
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-195.99
Return on Equity (TTM)
-118.28

Latest News

BRIEF-Obalon Reports Q1 Loss Per Share $0.71

* Q1 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Obalon Therapeutics Q4 Loss Per Share $0.60

* OBALON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Obalon Therapeutics Says Audit Committee's Investigation Into Purported Whistleblower Complaint Concluded Allegations Are Meritless

* OBALON THERAPEUTICS - AUDIT COMMITTEE COMPLETED INVESTIGATION INTO PURPORTED WHISTLEBLOWER COMPLAINT; CONCLUDED ALLEGATIONS ARE MERITLESS

Obalon cancels offering after allegation on accounting practices

Obalon Therapeutics Inc said on Tuesday it canceled a stock offering after the medical device maker, known for its swallowable balloons that aid in weight loss, was accused of improper accounting practices.

BRIEF-Obalon Therapeutics prices offering of 5.5 mln shares at $5.50 per share

* OBALON THERAPEUTICS INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF COMMON STOCK AT A OFFERING PRICE OF $5.50 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Obalon Therapeutics Announces Proposed Public Offering Of $35 Mln Shares

* OBALON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Obalon Therapeutics Q3 loss per share $0.55

* Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Obalon Therapeutics & Sono Bello announce agreement to offer novel weight loss treatment

* Obalon Therapeutics Inc and Sono Bello announce agreement to offer novel weight loss treatment in Sono Bello centers

BRIEF-Obalon Therapeutics files for mixed shelf of up to $100 mln

* Says in addition, selling stockholder may offer and sell up to 150,000 shares of co's common stock Source text: http://bit.ly/2z5bZGj Further company coverage:

BRIEF-Obalon Q2 loss per share $0.46

* Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S

BRIEF-Obalon receives regulatory approvals to commercialize in select Middle East markets

* Obalon receives regulatory approvals to commercialize in select middle east markets

BRIEF-Obalon Q1 loss per share $0.47

* Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Obalon Therapeutics Q4 loss per share $0.51

* Obalon Therapeutics Inc announces fourth quarter and full year 2016 financial results

BRIEF-Obalon announces initial commercial patient placements of the first and only swallowable, FDA-approved balloon system for weight loss

* Obalon announces initial commercial patient placements of the first and only swallowable, FDA-approved balloon system for weight loss Source text for Eikon: Further company coverage:

BRIEF-Obalon Therapeutics reports Q3 loss per share $5.46

* Q3 revenue $800,000 versus I/B/E/S view $703,000 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up